Transaction · 0001193125-26-421529

Buell Jennifer

Buell Jennifer, CEO, reported a transaction classified as exercise at MiNK Therapeutics, Inc. involving 23191.000000 shares. Reported holdings after the transaction were 81133.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

exerciseSEC transaction code MCEO
INKTMiNK Therapeutics, Inc.
Trade date
Oct 11, 2026
Filing date
Oct 14, 2026
View on SEC Insider profile
Estimated value—Shares × reported price
Shares traded23.1kPrice unknown
Holdings after81.1kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

INKT price since this filing

Daily closing prices, with the filing date and available return windows
INKT · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -5.7%1w ago +0.0%1d ago +0.0%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
exercise
Code M
Identifier
0001193125-26-421529
Common Stock
Transaction date
Oct 11, 2026
Filed Oct 14, 2026, 06:36 PM · 3d delay
Shares
23,191 sh
Price unknown
Estimated value
—
Computed from shares × price
Holdings after
81,133 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership Large Holdings Increase
Filing-only score

-2 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • missing_price-8 points

    price_cents is null

    Missing price reduces confidence in value-based signals.
Missing facts
  • price_cents
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Executive Officer

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MiNK Therapeutics, Inc. (the "Company").

  2. F2

    Represents sales of shares, as a consequence of the vesting of restricted stock units, solely to satisfy tax withholding obligations incurred upon vesting.

  3. F3

    Represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.33 to $10.61. The reporting person undertakes to provide to the Company, any shareholder o…

  4. F4

    On October 11, 2023 the reporting person was granted RSUs under the Company's 2021 Equity Incentive Plan, vesting in three substantially equal annual installments on each of the third, fourth and fift…

Original filing · 0001193125-26-421529
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

INKT